Fibrobiologics Inc (FBLG) has a current Price-to-Book (P/B) ratio of 92.66. Compared to its 3-year average P/B ratio of 33.04, the current P/B ratio is approximately 180.43% higher. Relative to its 5-year average P/B ratio of 33.04, the current P/B ratio is about 180.43% higher. Fibrobiologics Inc (FBLG) has a Forward Free Cash Flow (FCF) yield of approximately -104.43%. Compared to its 3-year average FCF yield of -31.83%, the current FCF yield is approximately 228.04% lower. Relative to its 5-year average FCF yield of -31.83%, the current FCF yield is about 228.04% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for FBLG competitors is 9.97, providing a benchmark for relative valuation. Fibrobiologics Inc Corp (FBLG.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of FBLG increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of FBLG in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is FBLG currently overvalued or undervalued?

What is Fibrobiologics Inc (FBLG) fair value?

FBLG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Fibrobiologics Inc (FBLG) is between to according to relative valuation method.

How does FBLG's valuation metrics compare to the industry average?

The average P/S ratio for FBLG's competitors is 9.97, providing a benchmark for relative valuation. Fibrobiologics Inc Corp (FBLG) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Fibrobiologics Inc (FBLG) as of Mar 02 2026?

As of Mar 02 2026, Fibrobiologics Inc (FBLG) has a P/B ratio of 92.66. This indicates that the market values FBLG at 92.66 times its book value.

What is the current FCF Yield for Fibrobiologics Inc (FBLG) as of Mar 02 2026?

As of Mar 02 2026, Fibrobiologics Inc (FBLG) has a FCF Yield of -104.43%. This means that for every dollar of Fibrobiologics Inc's market capitalization, the company generates -104.43 cents in free cash flow.

What is the current Forward P/E ratio for Fibrobiologics Inc (FBLG) as of Mar 02 2026?

As of Mar 02 2026, Fibrobiologics Inc (FBLG) has a Forward P/E ratio of -0.67. This means the market is willing to pay $-0.67 for every dollar of Fibrobiologics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Fibrobiologics Inc (FBLG) as of Mar 02 2026?

As of Mar 02 2026, Fibrobiologics Inc (FBLG) has a Forward P/S ratio of 0.00. This means the market is valuing FBLG at $0.00 for every dollar of expected revenue over the next 12 months.

FBLG Valuation